CLINICAL_TRIALS
trial_result
· 2011-07-14
Clinical Trial Update: Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma [Phase 1]
Summary
Phase 1 dose-escalation and safety study of a radiopharmaceutical 188Re-PTI-6D2 in metastatic melanoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pain Therapeutics | Conditions: Metastatic Melanoma | Phase 1 | Status: COMPLETED